Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

A Phase II Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) administered intravenously to Subjects With Atopic Dermatitis (AD)

January 21, 2014

This study is currently recruiting participants. Study is being conducted in 2 centers in NYC (Rockefeller University and Mount Sinai Medical Center)

Sponsor: Rockefeller University

Information provided by: Rockefeller University Identifier: NCT01941537

Purpose: Atopic dermatitis (AD) is a common inflammatory skin disorder that adversely affects most aspects of everyday life in majority of patients. It has a prevalence of up to 3-4% of adults and up to 25% among children. AD has a complex pathogenesis, characterized by: 1) immune activation with increased numbers of T-cells, dendritic cells (DCs), and increased expression of inflammatory molecules 2) marked epidermal hyperplasia in chronic diseased skin, and 3) defective barrier function with increased trans-epidermal water loss (TEWL) and decreased lipids, reflecting underlying alterations in keratinocyte differentiation.

AD is predominantly a Th2 (IL-4, IL-13, and IL-31) disease, and recently was also found to be a “Th22” (IL-22) disease. ILV-094 is an anti IL-22 antibody and therefore should reverse the immune activation of AD. This study is being done to assess the safety, tolerability, clinical efficacy, and mechanism of action of ILV-094 in patients with AD.

Name/Title of the Principal Investigator: Dr. Emma Guttman, MD/PhD

Contact Information:
Saakshi Khattri, MD – Research Associate
1230 York Avenue
New York, NY 10065
Business number: 212.327.8354 ext 8333
Fax number: 212.327.8232
Recruitment Office: 1.800.782.2737


For more information, please visit: